Physician profile
Robert Appleton
NPI 1861464273
$1,379.83
in general payments reported to CMS, 2019-2025
26 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.05 · 2020: $20.44 · 2021: $192 · 2022: $273 · 2023: $280 · 2024: $261 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $415.57 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Regeneron Healthcare Solutions, INC. | $153.46 | 2022-2024 | Dupixent |
| Novo Nordisk INC | $83.76 | 2022-2024 | Sogroya |
| Baxter Healthcare | $68.89 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Neurelis, INC. | $65.53 | 2022-2024 | Valtoco |
| Supernus Pharmaceuticals, INC. | $62.41 | 2021-2025 | Qelbree |
| Nestle Healthcare Nutrition INC. | $53.71 | 2021-2023 | |
| Sobi, INC | $52.01 | 2019 | |
| Ptc Therapeutics, INC. | $46.97 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $42.55 | 2025 | Bylvay |
| Kyowa Kirin, INC. | $40.87 | 2023-2024 | Crysvita |
| Qol Medical, LLC | $25.59 | 2025 | Sucraid |
| Livanova USA, INC. | $23.80 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.41 | 2025 | Amvuttra |
| Pierre Fabre Pharmaceuticals, INC. | $21.37 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $21.33 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.28 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.03 | 2021 | |
| Mirum Pharmaceuticals, INC. | $19.57 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.09 | 2024 | |
| Azurity Pharmaceuticals, INC. | $18.02 | 2025 | Triptodur |
| Tolmar, INC. | $17.91 | 2024 | |
| Zogenix INC. | $17.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.12 | 2019 | |
| Sk Life Science, INC. | $14.85 | 2022 | |
| Albireo Pharma, INC. | $14.54 | 2023 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Appleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.